Glucocorticoid corticosteroids for Duchenne muscular dystrophy

德菲扎科特 医学 杜氏肌营养不良 神经肌肉疾病 物理疗法 肌营养不良 浪费的 强的松 梅德林 儿科 荟萃分析 疾病 内科学 政治学 法学
作者
Adnan Y. Manzur,Thierry Küntzer,Mike Pike,A V Swan
出处
期刊:Cochrane Database of Systematic Reviews [Cochrane]
被引量:400
标识
DOI:10.1002/14651858.cd003725.pub3
摘要

Background Duchenne muscular dystrophy (DMD) is the most common muscular dystrophy of childhood. This incurable disease is characterised by muscle wasting and loss of walking ability leading to complete wheelchair dependence by 13 years of age. Prolongation of walking is one of the major aims of treatment. Objectives The aim of this review was to assess whether glucocorticoid corticosteroids stabilize or improve muscle strength and walking in boys with DMD. Search methods This is an update of the Cochrane systematic review first published in 2004 (Manzur 2004). We searched the Cochrane Neuromuscular Disease Group Trials Register (August 2006) using the term 'Duchenne muscular dystrophy'. We also searched MEDLINE (January 1966 to July 2007), EMBASE (January 1980 to August 2006), CINAHL and LILACS (January 1982 to August 2006). We wrote to authors of published studies and other experts in this disease to help identify other trials, checked the references in the identified trials and hand searched the abstracts of relevant journals. Selection criteria Types of studies: randomised or quasi‐randomised trials. Types of participants: all patients with a definite diagnosis of Duchenne muscular dystrophy. Types of interventions: glucocorticoids such as prednisone, prednisolone, deflazacort or others, with a minimum treatment period of three months. Primary outcome measure: prolongation of walking (independent walking without long leg calipers). Secondary outcome measures: strength outcome measures, manual muscle strength testing using Medical Research Council strength scores, functional outcome measures and adverse events. Data collection and analysis We identified six randomised controlled trials that met the inclusion criteria for our review, and one of these (Beenakker 2005) is a new addition to this update, as it was published subsequent to our first review (Manzur 2004). Two review authors independently selected the trials for the review and assessed methodological quality. Data extraction and inputting were double‐checked. Main results Primary outcome measure: data from one small study used prolongation of walking as an outcome measure and did not show significant benefit. Secondary outcome measures: The meta‐analysis of the results from four randomised controlled trials with altogether 249 participants showed that glucocorticoid corticosteroids improved muscle strength and function over six months. Improvements were seen in time taken to rise from the floor (Gowers' time), nine metres walking time, four‐stair climbing time, ability to lift weights, leg function grade and forced vital capacity. One randomised controlled trial with altogether 28 participants showed that glucocorticoid corticosteroids stabilize muscle strength and function for up to two years. The most effective prednisolone regime appears to be 0.75 mg/kg/day, given in a daily dose regime. Not enough data were available to compare efficacy of prednisone with deflazacort. Adverse effects: Excessive weight gain, behavioural abnormalities, cushingoid appearance and excessive hair growth were all more common with glucocorticoid corticosteroids than placebo. Long‐term adverse effects of glucocorticoid therapy could not be evaluated because of the short‐term duration of the randomised studies. Non‐randomised studies: A number of non‐randomised studies with important efficacy and adverse effects data are tabulated and discussed. Authors' conclusions There is evidence from randomised controlled studies that glucocorticoid corticosteroid therapy in Duchenne muscular dystrophy improves muscle strength and function in the short‐term (six months to two years). The most effective prednisolone regime appears to be 0.75 mg/kg/day, given daily. In the short term, adverse effects were significantly more common but not clinically severe. Long‐term benefits and hazards of glucocorticoid treatment cannot be evaluated from the currently published randomised studies. Non‐randomised studies support the conclusions of functional benefits but also identify clinically significant adverse effects of long‐term treatment. These benefits and adverse effects have implications for future research studies and clinical practice.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
淡淡酬海完成签到,获得积分20
1秒前
three发布了新的文献求助30
1秒前
脑洞疼应助罗永昊采纳,获得10
1秒前
搜集达人应助gaoyi12356采纳,获得10
1秒前
共享精神应助jackie采纳,获得10
2秒前
tunerling完成签到,获得积分10
2秒前
zomozo发布了新的文献求助10
3秒前
藜藜藜在乎你完成签到 ,获得积分10
3秒前
4秒前
滴滴滴完成签到,获得积分20
4秒前
6秒前
GBRUCE完成签到,获得积分10
6秒前
斯文败类应助KM比比采纳,获得10
6秒前
7秒前
jackie完成签到,获得积分10
7秒前
8秒前
冷静新烟发布了新的文献求助10
8秒前
英俊的铭应助生动的踏歌采纳,获得30
8秒前
9秒前
9秒前
10秒前
10秒前
最蠢的讨厌鬼完成签到,获得积分10
11秒前
量子星尘发布了新的文献求助10
11秒前
酷波er应助JohnLemon采纳,获得10
11秒前
神棍喜来乐完成签到,获得积分10
11秒前
淡淡智宸发布了新的文献求助10
13秒前
Lucas应助怪咖采纳,获得10
13秒前
13秒前
if完成签到 ,获得积分10
13秒前
yuzi发布了新的文献求助10
13秒前
zcl完成签到,获得积分20
14秒前
胡言乱语完成签到,获得积分10
14秒前
科研饼发布了新的文献求助10
15秒前
钻石发布了新的文献求助30
15秒前
three完成签到,获得积分20
16秒前
fd163c发布了新的文献求助20
16秒前
16秒前
小武wwwww完成签到 ,获得积分10
17秒前
lll完成签到,获得积分10
17秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 1000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3978415
求助须知:如何正确求助?哪些是违规求助? 3522416
关于积分的说明 11213317
捐赠科研通 3259798
什么是DOI,文献DOI怎么找? 1799678
邀请新用户注册赠送积分活动 878563
科研通“疑难数据库(出版商)”最低求助积分说明 806987